When to Start Heparin Drip After Stopping Eliquis (Apixaban)
In most clinical situations, bridging with a heparin drip is NOT necessary when discontinuing apixaban before surgery or procedures. 1, 2
Key Principle: Bridging is Generally Not Needed
The most important concept is that apixaban has a short half-life (7-8 hours) and predictable pharmacokinetics, making heparin bridging unnecessary in the vast majority of cases 1. The French perioperative guidelines explicitly state: "There is no need for preoperative heparin bridging (UFH or LMWH) except for very thrombotic high-risk" 1.
When Heparin Bridging IS Indicated
Heparin bridging should only be considered in very high thrombotic risk situations 1, 3:
- Acute HIT (heparin-induced thrombocytopenia) within the past month
- Recent thromboembolic event (<3 months)
- Recurrent thromboembolic events
- Mechanical heart valves
- Atrial fibrillation with prior embolic stroke
Timing for Switching from Apixaban to Heparin
If bridging is deemed necessary for very high-risk patients, the FDA label provides clear guidance 4:
"Discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken" 4
This means:
- Stop apixaban at its scheduled time
- Start heparin infusion immediately at the time the next apixaban dose would have been due (12 hours after the last dose for twice-daily dosing)
- No gap or overlap is needed
Standard Perioperative Management (No Bridging)
For elective procedures, the evidence-based approach is 2, 4:
Low-to-moderate bleeding risk procedures:
- Stop apixaban 24 hours before (skip 1 dose) 5, 2
- This provides approximately 3 half-lives of clearance
- Resume 24 hours after procedure once hemostasis is established 4
High bleeding risk procedures:
Special Considerations
Renal impairment (CrCl 15-29 mL/min):
- Extend stopping time to 36-48 hours even for low-risk procedures 5
- 25% of apixaban is renally cleared 6
Very high bleeding risk (neurosurgery, spinal procedures):
Common Pitfall to Avoid
Do not reflexively bridge all anticoagulated patients with heparin. This outdated practice increases bleeding risk without reducing thrombotic events in most patients 1, 2. The PAUSE trial demonstrated excellent safety outcomes with standardized DOAC interruption without bridging: only 0.16% arterial thromboembolism rate and 1.35% major bleeding rate in apixaban patients 2.
The 2022 CHEST guidelines confirm this approach, showing that the pharmacokinetic-based interruption strategy (1-2 days for most procedures) is safe and effective without heparin bridging 2.